Abstract:The highly successful epidemic of healthcare-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) ST239 is a growing concern worldwide, due to its progressive adaptation to the highly selective environment of the healthcare system. HA-MRSA ST239 display the reduced virulence and successfully colonize in hospital settings, while the emergent community-associated MRSA (CA-MRSA) maintain full virulence and cause infections in the community environment. Our aim was to investigate what enables S. aureus ST239 to be highly adaptive under hospital circumstances and gradually progress to a series of widespread invasive infections. We found that spa expression of HA-MRSA ST239 is much higher than that of CA-SA ST398. And we discovered that the highly production of staphylococcal protein A (SpA), having no concern with spa gene structure, enhances nasal colonization and cell adhesion in ST239. S. aureus ST239 defends against the adaptive immune response by resisting phagocytosis and inducing apoptosis of B cells through expression of surface-anchored and released protein A, facilitating its dissemination within the circulatory system to other organs. Protein A also plays another key role in subverting the host immune response through its ability to induce early shedding of TNF-α receptor 1 (TNFR1) from phagocytic cells. The increased levels of soluble TNFR1 present during experimental S. aureus ST239 infection may neutralize circulating TNF-α and impair the host inflammatory response. Protein A is also a virulence factor, as tested in our bacteremia model in mice, contributing to the durative tissue damage of abscess formation sites in ST239 infection. These functions of protein A eventually benefit to widespread infections of S. aureus ST239. We draw the conclusion that Staphylococcal Protein A may be a crucial determinant in the colonization and immune evasion of ST239 infections, contributing to persistent spread in the hospital settings. These results suggest that antibodies against protein A may provide insights into the development of novel treatments against S. aureus, especially HA-MRSA.

C-terminus of TRAP in Staphylococcus Can Enhance the Activity of Lysozyme and Lysostaphin

Trimeric Coiled-Coil Domain of Human Pulmonary Surfactant Protein D Enhances Zinc-Binding Ability and Biologic Activity of Soluble TRAIL.

A Novel Peptide Screened by Phage Display Can Mimic TRAP Antigen Epitope Against Staphylococcus Aureus Infections

The Preliminary Study on TRAP Polyclonal Antibodies

Inhibition of Staphylococcus aureus pathogenesis in vitro and in vivo by RAP-binding peptides.

Cloning and Expression of TRAP in E.coli

Novel staphylococcal glycosyltransferases SdgA and SdgB mediate immunogenicity and protection of virulence-associated cell wall proteins.

Overcoming Planktonic and Intracellular Staphylococcus Aureus-Associated Infection with a Cell-Penetrating Peptide-Conjugated Antimicrobial Peptide

Staphylococcal Protein A Promotes Colonization and Immune Evasion of the Epidemic Healthcare-Associated MRSA ST239.

Improving the Activity of Tryptophan Synthetase via a Nucleic Acid Scaffold

Oligopeptide Targeting Sortase A as Potential Anti-infective Therapy for Staphylococcus aureus .

A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation

Combatting Antibiotic-Resistant Staphylococcus aureus: Discovery of TST1N-224, a Potent Inhibitor Targeting Response Regulator VraRC, through Pharmacophore-Based Screening and Molecular Characterizations

Triple-acting Lytic Enzyme Treatment of Drug-Resistant and Intracellular Staphylococcus aureus

Staphylococcus epidermidis ΔSortase A strain elicits protective immunity against Staphylococcus aureus infection

A temperature-sensitive trpS mutation interferes with trp RNA-binding attenuation protein (TRAP) regulation of trp gene expression in Bacillus subtilis

TRPA1 Influences Staphylococcus Aureus Skin Infection in Mice and Associates with HIF-1a and MAPK Pathway Modulation

Expression and characterization of the new antimicrobial peptide AP138L-arg26 anti Staphylococcus aureus

The lysostaphin endopeptidase resistance gene (epr) specifies modification of peptidoglycan cross bridges in Staphylococcus simulans and Staphylococcus aureus

Anti-infective therapy using species-specific activators of Staphylococcus aureus ClpP

SaeR As a Novel Target for Antivirulence Therapy Against Staphylococcus Aureus